To implement the plans and deployments of the Shenzhen Municipal Party Committee and Municipal Government regarding the development of the "20+8" strategic emerging industries and future industry clusters, and to promote innovation and industrial development in the fields of cell and gene as well as brain science, on September 11, Shenzhen University of Advanced Technology (abbreviated as "SUAT"), the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (abbreviated as "SIAT"), and Luye Pharma (Shenzhen) Co., Ltd. (abbreviated as "Shenzhen Luye") jointly signed a cooperation agreement. The three cooperating parties will fully leverage their respective advantages in scientific research, technology, and market aspects, with a focus on advancing technological R&D innovation and application development in the biomedicine field, contributing to the progress of biotechnology.

Attendees at the signing ceremony included Fan Jianping, Director of the Preparatory Office of SUAT; Wu Chuangzhi, Party Secretary of SIAT; Liu Dianbo, Chairman of the Board of Luye Life Sciences Group; and Chen Xi, Deputy General Manager of Shenzhen Investment Holdings Capital Co., Ltd.

Fan Jianping stated that, as a new-type research university, SUAT is always committed to promoting the combination of scientific research innovation and industrial applications through integration of industry and education as well as science and education. In the future, SUAT will transform the best research conditions and talent cultivation models into tangible results, cultivate more outstanding talents, and promote innovative development in the life sciences field.

Wu Chuangzhi stated that, as a national research institution, SIAT is always committed to frontier technology research and innovation, with years of development in multiple directions such as cell technology, gene technology, and brain science research, boasting a strong talent team, leading technological development, and abundant research achievements. In the future, SIAT will fully leverage its advantages in research and talent, deeply integrating technological innovation and industrial innovation with Shenzhen Luye to contribute to the development of new quality productive forces.

Liu Dianbo stated that Luye Pharma Group focuses on the R&D, production, and sales of innovative drugs in areas such as central nervous system, oncology, cardiovascular, and metabolic diseases. It is hoped that this cooperation can attract a group of international high-end talents and high-end upstream and downstream biomedicine industries to settle in Shenzhen, forming a biomedicine industry cluster in Shenzhen and accelerating Shenzhen's biomedicine industry to enter the first tier.

At the recently held 2024 Shenzhen Biomedicine Industry Investment Promotion Conference, Liu Chenli, Deputy Director of SIAT, also mentioned this cooperation. He stated—

SIAT actively explores cooperation modes such as "turnkey" translation, "hand-in-hand" development, and "order-based" R&D. Through cooperation with enterprises like Shenzhen Luye, it continuously forms a strong technological synergy based in Shenzhen and serving the Greater Bay Area, solidly promoting deep integration of technological innovation and industrial innovation, accelerating the translation of scientific and technological achievements into real productive forces, and making greater contributions to building a strong nation in science and technology and promoting high-quality economic development.

It is reported that the cooperating parties will focus on biomedicine, centering on cell and gene as well as brain science, exploring new modes of scientific and technological achievement translation such as "hand-in-hand" development and "order-based" R&D, and conducting extensive cooperation at multiple levels in frontier technology research, new product development, technology platform establishment, and talent cultivation.

In the cell and gene field, through technological innovation and project tackling, they will jointly explore treatment technologies, enhance source innovation capabilities, promote the translation and application of a batch of technological achievements, and achieve more breakthroughs especially in precision medicine and personalized treatment.

In the brain science field, focusing on new drug R&D for brain science diseases, they will accelerate the industrialization of a batch of frontier technological achievements from the laboratory, using the "key of innovation" to unlock the "code of life," contributing more to life science research and industrial development in Shenzhen and even nationwide.